QUÉBEC CITY, April 1, 2014
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ)
(the "Company") today announced that a poster will be presented on
AEZS-134, a highly potent and selective ATP competitive Erk
inhibitor, during the American Association for Cancer Research
(AACR) Annual Meeting, which will be held April 5-9, 2014 in San
Diego, California.
| Abstract #3711: |
"Erk Inhibition as a Therapeutic Option for the Treatment of
Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P.
Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M.
Teifel. |
| |
|
| Presenter: |
Irene Seipelt, PhD, Director, Preclinical Development at
Aeterna Zentaris |
| |
|
| Poster
Session: |
Experimental and Molecular Therapeutics 26 |
| |
|
| Date & Time: |
Tuesday, April 8, 2014, 8 am-12 pm (Pacific time) |
| |
|
| Venue: |
Hall A-E, poster section 31, San Diego Convention Center |
About AEZS-134
AEZS-134 is an integral part of the Company's kinase research
program comprising the investigation of different compounds for
single Erk inhibition, single PI3K inhibition and
dual Erk/PI3K kinase inhibition. AEZS-134 selectively inhibits
the kinase activity of Erk. AEZS-134 was discovered using the
Company's proprietary compound library and high throughput
screening technology. AEZS-134 is available for partnering.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds at
various stages of development. For more information, visit
www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.